Comparing Two Biopsy Methods During Colonoscopy in Inflammatory Bowel Disease

Trial details

Who runs it

Abramson Cancer Center at Penn Medicine

Trial code

NCT06560021

Record updated

17 August 2026

Original description

The proposed study is a multicenter parallel group clinical trial that will include 821 evaluable patients per group who will be randomly assigned to either high definition white light colonoscopy (HDWLC) with targeted biopsies plus 2 random biopsies in 4 segments to assess for inflammation (limited biopsy strategy) or HDWLC with targeted biopsies plus 4 biopsies every 10 cm throughout the colon, at a minimum in all segments of the colon known to have been affected by IBD at any time, regardless of the extent of disease (random biopsy strategy). Participants will be followed until total proctocolectomy or the end of the study period to determine whether the two methods of surveillance colonoscopy are associated with detection of dysplasia or sessile serrated adenoma at follow-up colonoscopy. Follow-up via chart review may continue for up to 15 years from enrollment.Read full original descriptionShow less

A Randomized Trial of the Utility of Random Biopsies in Patients With Inflammatory Bowel Disease

The proposed study is a multicenter parallel group clinical trial that will include 821 evaluable patients per group who will be randomly assigned to either high definition white light colonoscopy (HDWLC) with targeted biopsies plus 2 random biopsies in 4 segments to assess for inflammation (limited biopsy strategy) or HDWLC with targeted biopsies plus 4 biopsies every 10 cm throughout the colon, at a minimum in all segments of the colon known to have been affected by IBD at any time, regardless of the extent of disease (random biopsy strategy). Participants will be followed until total proctocolectomy or the end of the study period to determine whether the two methods of surveillance colonoscopy are associated with detection of dysplasia or sessile serrated adenoma at follow-up colonoscopy. Follow-up via chart review may continue for up to 15 years from enrollment.

Inclusion: Diagnosis of left-sided (greater than 15 cm of disease but not beyond the splenic flexure) or extensive (extending beyond the splenic flexure) ulcerative colitis or IBD-U or colonic Crohn's disease involving at least 1/3 of the colon (defined as 2 segments of the remaining colon; segments include right colon, transverse colon, left colon and rectum); Disease duration must meet one of the following criteria:; onset of symptoms of IBD at least 8 years prior; diagnosis of IBD at least 8 years prior; diagnosis of IBD for any duration if other risk factors for colon cancer are present including: concomitant diagnosis of primary sclerosing cholangitis, personal history of dysplasia, sessile serrated adenoma or right sided hyperplastic polyps greater than 10mm in diameter, or a family history of colon cancer in a first degree relative or two second degree relatives; Scheduled to undergo colonoscopy as part of routine care; At least one indication for the index colonoscopy must be to perform dysplasia surveillance.

Exclusion: Any condition that the endoscopist feels is a contraindication to random biopsies; History of visible (high or low grade) dysplasia not completely removed; History of sessile serrated adenoma not completely removed; History of colorectal cancer; Any condition for which the endoscopist feels that pancolonic contrast or virtual chromoendoscopy is mandatory; Less than 2 segments of the remaining colon have ever been involved with IBD; Colonoscopy* in the last 11 months unless the colonoscopy:; was determined by the endoscopist to be insufficient for dysplasia surveillance and,; did not include a diagnosis of dysplasia or sessile serrated adenoma. *Does not include sigmoidoscopy; Inability to provide informed consent.

ClinicalTrials.gov NCT06560021